By Abigail Townsend
Date: Wednesday 20 Oct 2021
(Sharecast News) - Biogen raised its full-year earnings guidance on Wednesday, despite weak sales of breakthrough Alzheimer's drug Aduhelm.
| Currency | US Dollars |
| Share Price | $ 171.86 |
| Change Today | $ 6.48 |
| % Change | 3.92 % |
| 52 Week High | $187.62 |
| 52 Week Low | $118.84 |
| Volume | 742,771 |
| Shares Issued | 145.80m |
| Market Cap | $25,057m |
| RiskGrade | 259 |
| Strong Buy | 8 |
| Buy | 6 |
| Neutral | 19 |
| Sell | 1 |
| Strong Sell | 0 |
| Total | 34 |

| Time | Volume / Share Price |
| 14:31 | 100 @ $171.86 |
| 14:31 | 100 @ $171.82 |
| 14:31 | 100 @ $171.83 |
| 14:30 | 100 @ $171.90 |
| 14:30 | 100 @ $171.89 |
You are here: research